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Abstract: Independent individualization of multiple product attributes, such as dose and drug release,
is a crucial overarching requirement of pharmaceutical products for individualized therapy as is the
unified integration of individualized product design with the processes and production that drive
patient access to such therapy. Individualization intrinsically demands a marked increase in the
number of product variants to suit smaller, more stratified patient populations. One established design
strategy to provide enhanced product variety is product modularization. Despite existing customized
and/or modular product design concepts, multifunctional individualization in an integrated manner
is still strikingly absent in pharma. Consequently, this study aims to demonstrate multifunctional
individualization through a modular product design capable of providing an increased variety
of release profiles independent of dose and dosage form size. To further exhibit that increased
product variety is attainable even with a low degree of product modularity, the modular design was
based upon a fixed target dosage form size of approximately 200 mm3 comprising two modules,
approximately 100 mm3 each. Each module contained a melt-extruded and molded formulation
of 40% w/w metoprolol succinate in a PEG1500 and Kollidon® VA64 erodible hydrophilic matrix
surrounded by polylactic acid and/or polyvinyl acetate as additional release rate-controlling polymers.
Drug release testing confirmed the generation of predictable, combined drug release kinetics for
dosage forms, independent of dose, based on a product’s constituent modules and enhanced product
variety through a minimum of six dosage form release profiles from only three module variants. Based
on these initial results, the potential of the reconfigurable modular product design concept is discussed
for unified integration into a pharmaceutical mass customization/mass personalization context.
Keywords: modular dosage form; reconfiguration; product variety; oral controlled release; melt-based
processing; individualized therapy
1. Introduction
The provision of individualized pharmaceutical therapy, which ultimately aims to elicit optimal
therapeutic outcomes a priori from all patients, requires the integration of key patient attributes into the
design and manufacture of pharmaceutical products [1–10]. Recently, we presented a patient-centric
framework of design requirements for individualized pharmaceutical products [3]. This was founded
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on the integration of key patient attributes and drivers for individualized therapy across three primary
dimensions (biological, behavioral, and environmental) and a co-dimension (patient preference) into
the design of pharmaceutical products, based upon a critical review of underpinning patient needs.
Such integration reveals that simultaneous and independent individualization of multiple product
features, such as the dose and drug release functionalities, in a controlled and predictable manner, is
critical to tailoring products to fully meet the needs of all individuals [3].
As target patient segments become progressively smaller, with each segment having unique
needs from the pharmaceutical product, enabling simultaneous and independent individualization of
multiple product features, i.e., multifunctional individualization, will demand a marked increase in the
number of product variants. This encompasses, for example, simultaneous provision of individualized
dosing [3,11–15] and individualized drug release [3,16–20], where required [3]. Individualized dosing
demands an increased number of dose strengths within a pre-established dose range. Similarly,
individualized drug release demands an increased number of unique formulation-driven release
profiles for a given active pharmaceutical ingredient (API) to enable robust individualized in vivo
drug release and uptake and/or synchronized administration of multiple drugs [3]. However, under
the current mass production paradigm, which is characterized by economies of scale, the provision
of an increased number of product variants is constrained by limits in technical realizability and
economic feasibility at low volumes [3,21–23]. Therefore, a shift towards alternative production
approaches, such as mass customization/mass personalization [24–28], characterized by economies of
scope, becomes critical to meet this product variety–volume complexity challenge and gain patient
and societal benefits from individualized therapies [2,3]. In non-pharmaceutical branches of industry,
established mass customization concepts like process flexibility, product modularity, and postponement
(i.e., delayed point of product differentiation in the production chain) lend themselves to efficient
management of product variety [3,29–31]. However, with the exception of process flexibility as a
means to extend the manufacturing platform capability [32–35], such concepts remain inadequately
addressed in a pharmaceutical context. For pharmaceutical products, providing the enhanced product
variety necessary to fulfill the abovementioned individualized dose and individualized drug release
requirements will rely on unified integration of these mass customization principles into both the
design of the product and its manufacture. In this way, the required variety can be technically
delivered alongside affordability and efficiency at smaller volumes. So far, although product design
opportunities for individualization have been demonstrated, their holistic integration with a processing
and production context for the provision of affordable individualized therapy is strikingly absent.
The aim of our study is to demonstrate multifunctional individualization by modular dosage
forms through a product design concept capable of providing an increased variety of release profiles
independent of the dose and size of the dosage form. In doing so, with a focus on the product platform
and specifically on product modularity as an approach to provide affordable variety [31,36], this work
explores and provides a basis for bridging the gap between established theoretical concepts of mass
customization/mass personalization and eventual application in a pharmaceutical context.
1.1. Theoretical Considerations: Pharmaceutical Product Modularization
Modular products have been defined previously as that which comprises building blocks or
modules [37], whereby each module delivers a unique function required for the product to perform as
intended [37,38]. These modules in turn consist of even smaller building blocks from which the module
is constructed. For the purpose of this article, these distinctions are denoted, in order of decreasing
size, as product (dosage form) > module > component. Modular pharmaceutical product archetypes
already exist both on the market and in academic research [17,39–57], including, for example, granules,
pellets, mini tablets, layered dosage forms, and compartmentalized structures, as well as the more
recently demonstrated combined API and flexible dose product architectures [22,52,58]. However,
these are currently designed to either promote process flexibility within the currently dominant mass
production paradigm or potentially product variety within a full customization context. Figure 1
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highlights the contrast between conventional modular product concepts and the proposed modular
product concept.
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Notably, Figure 1 exemplifies that an equivalent number of module variants in the conventional
and proposed concept yields different degrees of product variety (one product variant vs. > three
product variants in the example shown), with greater product variety accessible with the proposed
modular product concept. This is due to the fact that conventional modular product archetypes are
usually constructed by fixed assembly of modules into products [17,40,53,59–61]. Variety in the product
offering is typically attainable through iterative modifications of a single initial product design until
arriving at the variant of choice. Consequently, a greater number of module variants are required to
generate a greater number of product variants. The drawback with this approach is that approaching
lower volumes and higher variety of products is accompanied by a loss of economies of scale and an
inevitable trade-off between affordability and variety [23]. This explains why most demonstrated oral
dosage form modularization, even when some variety is present, still either exhibits interdependent
dosage form size, dose, and drug release kinetics and/or a choice between fixed dose and fixed drug
release kinetics at a given dosage form size [17,52,58,59,62–67]. From a product variety management
perspective, conventional modular concepts are therefore limited in their ability to simultaneously
deliver both the high variety and affordability necessary for individualization.
Recently, Siiskonen et al. have developed a customized product concept for modular pharmaceutical
products to address the requirement for enhanced product variety in the provision of individualized
therapy [68]. Building on the potential of this concept, which showed that 100 dose strengths were
attainable from only five module variants, our study extends the exploration of modular product
concepts towards multifunctional individualization, specifically for the independent provision
of an individualized dose and individualized drug release. Through reconfigurable assembly
(reconfiguration), our proposed concept explores the opportunity to realize a multitude of product
variants whilst supporting affordability (Figure 1). Reconfigurable assembly of modules into products
enables affordable variety by allowing a greater number of product variants to be generated from
relatively fewer module variants [69]. Unlike conventional modular concepts, where reconfiguration is
typically absent, product variety achieved through reconfiguration does not solely depend on module
variety. The product variant of choice for an individual is instead selected from a set of multiple
initial product designs. Provided that the concurrently developed product designs are based on an
appropriate balance between standardization and differentiation in their features, both variety and
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affordability may be achieved [31,36], effectively achieving economies of scope almost on par with
economies of scale.
1.2. Design of the Proposed Product Concept
Figure 2 illustrates key design features of the proposed modular product concept to provide
independent control of dose and drug release demonstrated through an increased variety of drug
release profiles in the product offering.
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us of composite, reconfigurable drug elease to increase rel ase profile variety.
e product was designed as a solid oral dosage form with a modular architecture. For the purpose
of this study, a dosage form was assu ed to comprise two ut of three p ssible module variants, i.e., a
low degree of product modularity. These three module variants were designed to provide unique drug
release profiles but contain the same dose. A key feature for simultaneous and independent tail ring of
the dose and drug release to an individual is the spatial separation of the dose- and release-contr lling
functionalities in the module variants. Reconfigurable assembly of these module variants into dosage
forms, c mbining either two identical or two dissimilar module variants, was designed to increas
ariety in resulting i vitr drug release profiles on the dosage form level for a single API-containing
drug product, without needing to i crease the number of module variants. Importantly, it was
only through one component (i.e., the lid) that variety in the release kinetics of the module variants
was introduced whilst other components (i.e., the cor and cup) remained fix d. Altogether, spatial
separation of features of interest supports multifunctionality, whereas r configurabl assembly of
odule variants into dos ge forms and a b lance between standardizatio and diff rentiatio of
submodular compo ents promote affordable variety. These characteristics therefore underpin th
suitability of this concept for tackling the product vari ty–volume c mplexity challenge.
Our work proposes and constitutes, to th best of the authors’ knowledge, a first demonstration
of a product concept that supports m ltifunctional individu lization whilst also meeting the challenge
from enhanced product variety management. Except for an early recommendation in our previous
work [3], for the purpose of affordable variety for individualized therapy, n ither multifunctional
indi idualization nor the provision of an increased variety of unique release profiles in a controlled
and predictable manner through rec nfiguration have been sugg sted or demonstrated yet.
The realization of th proposed concept is based on the hypothesis that, in the absence f
interactions between module variants, module variants with independently controlled dose- and drug
release-det rmining functionalities can tribute predictably and independently to the net dose and
drug release functio alities of the dosage f rm they co struct.
Although co-development f product and man facturing platforms i a mass customization
context is c cial to upport e hanced pharmaceutical product variety, especially at lower volumes,
for the purpose of monstrating our proposed concept, the product platform (with pecific focus
s lid oral dosage f rms) is co sider within the scope whereas manufacturing platforms, beyond
their t chnical ability to prototype with the int nded product performance, a e considered out of scope.
Since manufacturing networks are out of scope, scale-u and dedicated stability testing under varyi g
conditions relev nt to st rage and transport are also beyond the scope of this study.
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2. Materials and Methods
2.1. Materials
Metoprolol succinate (MS; MW 652.8 g/mol) was obtained from AstraZeneca (Gothenburg,
Sweden). Vinylpyrrolidone-vinyl acetate copolymer (VA64; Kollidon® VA64) was supplied by
BASF (Ludwigshafen, Germany). Polyethylene glycol 1500 (PEG1500; MW 1500 g/mol), sodium
phosphate dibasic dihydrate (MW 177.99 g/mol, assay ≥ 98.0%) and sodium phosphate monobasic
monohydrate (137.99 g/mol, assay ≥ 99.0%) were purchased from Sigma-Aldrich Chemie GmbH
(Steinheim, Germany). ZMorph polylactic acid (PLA) filament (white, 1.75 mm diameter) was obtained
from ZMorph S.A. (Wroclaw, Poland) and Aquasolve™ polyvinyl acetate (PVA) filament (natural,
1.75 mm diameter) was purchased from Formfutura BV (Nijmegen, Netherlands).
2.2. Methods
2.2.1. Technical Realization of the Product Concept
The module variants were constructed from submodular components whose structural design
and material selection provided each module variant with its respective dose and drug release
kinetics. The dose-controlling functionality of each module variant was derived from a standardized
drug-containing rapidly erodible polymeric core, intended to convey an identical dose to each module.
Two release-controlling submodular components were designed, one was standardized between
module variants (cup) and the other was customized for each module variant (lid). The standardized
water-insoluble PLA cup enclosed the bottom and sides of the core, allowing the surface area available
for drug release to remain constant during dissolution. The presence and/or type of lid provided the
module variants with their distinct drug release kinetics. Module variant 1 (MV1) with no lid was
designed to provide rapid drug release, module variant 2 (MV2) with a water-soluble lid of predefined
thickness was designed to generate a lag phase followed by rapid drug release from the core, and
module variant 3 (MV3) with a water-insoluble lid with a central orifice was designed to provide
slower initial drug release kinetics through the reduced area available for initial hydration of the core.
2.2.2. Fused Deposition Modeling (FDM)
Fused deposition modeling (FDM) was used to fabricate the cup and lid submodular components.
Digital models of the cup and lid were created as ‘.stl’ files using Autodesk® TinkerCAD™ (Autodesk,
Inc., San Rafael, CA, USA). The generated ‘.stl’ file was subsequently imported into Simplify3D®
(version 4.1.1., Simplify3D LLC, Cincinnati, OH, USA) for control of printing parameters and subsequent
printing. Critical cup and lid model dimensions are described in Figure 3.
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Figure  3.  Key  feature  dimensions  for  fused  deposition  modeling  (FDM)‐printed  submodular 
components, i.e., cup (left), soluble lid (middle), and insoluble lid (right), viewed upright (top row) 
and inverted (bottom row). 
Figure 3. Key feature dimensions for fused deposition modeling (FD )-printed submodular
components, i.e., cup (left), soluble lid (middle), and insoluble lid (right), viewed upright (top row) and
inverted (bottom row).
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A ZMorph VX multitool 3D printer (ZMorph S.A., Wroclaw, Poland), equipped with a single
0.3 mm diameter extrusion nozzle, was used to independently print the cup and lid submodular
components from PLA and PVA filaments, respectively, for downstream assembly. The lids were
designed with overhanging side walls and the cups and lids were all printed with matching 0.1 mm
layer heights to facilitate interlocking and adhesion and prevent dislodging of the lids once the modules
were assembled. Prior to the printing of each component, the build platform was leveled and heated to
60 ◦C to facilitate adhesion of the structures onto the platform. The set temperature for the nozzle was
200 ◦C, for both PLA cups and PVA lids.
2.2.3. Melt Extrusion of the Drug-Containing Filament
Hot melt extrusion (HME) was the first step in core fabrication and was selected in order to
obtain a homogeneous distribution of the drug in a carrier via HME’s dispersive and distributive
mixing. A formulation containing 40:20:40% w/w MS:PEG1500:VA64 was prepared by HME. This drug
concentration allowed a dose of approximately 25 mg MS (lower limit of marketed dose) to be
incorporated into each dosage form. The incorporation of both low molecular weight PEG and VA64
as carriers facilitated the melt molding and melt extrusion processes, respectively, whilst promoting
rapid drug release. MS powder, PEG1500, and VA64 powder were weighed in a weigh boat in a 2.5 g
batch size and mixed with a spatula until homogeneous upon visual inspection. HME was performed
using a 5 mL capacity Xplore micro compounder (Xplore Instruments BV, Sittard, The Netherlands),
affixed with conical mixing screws and a circular die, 1.5 mm in diameter. The physical mixtures were
fed via a hopper into the barrel maintained at a constant temperature profile of 80 ◦C and a screw speed
of 50 rpm during feeding and recirculation. This processing temperature was sufficiently low to allow
consistent feeding into the barrel without particle bridging in the hopper and an appropriate material
viscosity for consistent extrusion through the die and sufficiently high to operate within the motor load
(torque) limit of the extruder at the chosen batch size. After complete feeding (< 1 min), mixtures were
recirculated for 10 min to aid homogenization prior to extrusion through the die to obtain a cylindrical
filament, which was allowed to cool at room temperature. Ejection was force-controlled at 100 N until
a maximum screw speed of 400 rpm was reached. Filaments were stored in sealed plastic bags at room
temperature prior to further processing.
2.2.4. Melt Molding of Drug-Containing Cores
Melt molding was the second step in core fabrication. Empty PLA cups fabricated by FDM
were weighed in a Mettler MT5 analytical balance (Mettler Toledo, Greifensee, Zurich, Switzerland).
Melt extruded filaments were cut with a blade and manually filled into each PLA cup. The cups with
unmelted filaments were placed in an oven (Memmert GmbH + Co.KG, Schwabach, Germany) at
100 ◦C for 15 min, the shortest duration required to achieve molding at this temperature. A higher
temperature was required during melt molding than melt extrusion due to the absence of shear stress or
applied force from rotating screws in the former process. This melt molding temperature allowed the
molten formulation to fill the cup whilst the surrounding PLA cup maintained its structural integrity.
The selection of a melt molding process for core fabrication allowed the core formulation to form a good
seal with the inner bottom and sides of the surrounding PLA cup. In the absence of a lid, the exposed
surface area for subsequent hydration and drug release would be identical in all module variants.
The cups for MV1 and MV2 were filled completely in 2 sequential additions of 15 min each whereas the
cups for MV3 were overfilled in 3 sequential additions of 15 min each to prevent formation of an air
pocket beneath the MV3 lid orifice. The core-containing cups were weighed, and the mass of the cores
calculated. Filled cups were stored in closed plastic well plates at room temperature prior to analysis.
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2.2.5. Thermal Characterization
Thermogravimetric analysis (TGA) using a TGA/DSC 3+ STARe system instrument (Mettler Toledo,
Greifensee, Zurich, Switzerland) was performed on raw materials to determine the onset of thermal
degradation (Tdeg). Materials were weighed in open 100 µL aluminium crucibles and heated from
30 to 500 ◦C at 10 K/min under a nitrogen atmosphere set at a flow rate of 50 mL/min. Tdeg was reported
as the first observed deflection (mass loss) from the initial baseline in the weight vs. temperature
curve in the absence of water loss. Glass transition temperatures (Tg) and/or melting points (Tm) of
the raw materials and melt extruded filaments were probed between room temperature and below
Tdeg of the drug, which represents the range of storage and processing conditions for the materials.
Tg of raw materials below room temperature (MS and PEG1500) were obtained from existing literature.
These thermal events were measured by differential scanning calorimetry (DSC) in a DSC 2 STARe
system instrument (Mettler Toledo, Greifensee, Zurich, Switzerland). The samples were weighed
in 40 µL aluminium crucibles, which were sealed by lids with a pinhole for subsequent analysis.
The instrument was run in a heat-cool-heat cycle at 10 K/min under a 50 mL/min nitrogen atmosphere
from 25 to 170 ◦C. STARe software (version 16.00b, Mettler Toledo, Greifensee, Zurich, Switzerland) was
used for instrument control and subsequent analysis of thermograms. Tg values were determined at the
midpoint of the Tg range and Tm at the peak of the melting endotherm. Furthermore, the percentage
crystallinity of MS in the melt extruded filament was calculated by normalizing the melting enthalpy
of MS in the melt extruded filament to the melting enthalpy of the pure MS powder (100% crystallinity)
and to a nominal MS content of 40% w/w in the filament. All samples were prepared in triplicate
for analysis.
2.2.6. X-Ray Computed Microtomography (X-Ray µCT)
Non-destructive visualization of the module variants was performed using X-ray computed
microtomography (X-ray µCT). The assembled module variants comprising the cup, core, and affixed
lid (for MV2 and MV3) were analyzed intact using a high-resolution SkyScan 1272 instrument (Bruker,
Antwerp, Belgium), with a 50 kV, 181 µA X-ray source and a charge-coupled device (CCD) detector
fiber-optically coupled to a scintillator. SkyScan 1272 control software (v1.1.17, Bruker microCT,
Antwerp, Belgium) was used for instrument operation. Samples were imaged in batches of 4 at a
pixel size of 19.8 µm or smaller. Three-dimensional imaging was achieved by rotation through 180◦
with steps of 0.5◦ averaging 2 frames per position, with 3 × 3 binning, resulting in a resolution of
1344 pixels × 896 pixels and a total acquisition time of 23 min per batch. Image reconstruction was
performed from a batch of 4 objects using NRecon (v1.6.10.2, Bruker, Antwerp, Belgium) at a resolution
of 19.8 µm, adjusting misalignment, reducing ring artifacts, and applying beam hardening correction
(10%). During reconstruction, the subscans were fused in the z-direction and both x/y shift correction
and rotation correction were applied. DataViewer (v1.5.6.2, Bruker microCT, Antwerp, Belgium) was
used for data analysis. Core diameters for all module variants, lid thicknesses for MV2, and orifice
sizes for MV3 were obtained from DataViewer. The orifice diameter was measured for a 0.4 mm orifice
size although final drug release tests were conducted on MV3 with a 0.8 mm orifice size. A digital
caliper set at 0.8 mm was used to verify that 0.8 mm orifices were consistently printed.
2.2.7. In Vitro Drug Release and Drug Content Homogeneity
In vitro drug release testing of MS from the module variants, both alone and in combinations of
two module variants (to represent the dosage form variants), was carried out in duplicate using a USP
2 dissolution apparatus (Varian 705-DS, Agilent Technologies, Santa Clara, CA, USA) with a suspended
stainless-steel stationary basket (mesh size 8), which housed the sample. To prevent floating during
dissolution, the module variants were glued to the metal flap supplied with the stationary basket using
ethyl cyanoacrylate adhesive. The USP 2 apparatus was operated at 37 ± 1 ◦C, 50 rpm with 900 mL
pH 6.8 phosphate buffer (I = 0.1 M) and was equipped with an autosampler (Agilent 8000 Dissolution
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Sampling Station, Agilent Technologies, Santa Clara, CA, USA) programmed to withdraw 1.5 mL sample
aliquots at predefined time intervals without media replacement. Withdrawn aliquots were analyzed
by ultra-performance liquid chromatography coupled with ultraviolet spectroscopy (UPLC-UV) to
quantify MS concentration. For all drug release tests involving MV3, to eliminate the accumulation
of air from the dissolution medium at the orifice of MV3, the dissolution medium was stirred for 2 h
prior to commencement of the drug release test and the lid of the dissolution vessel was tapped gently
during dissolution at 0 min and 15 min, respectively.
Prior to USP 2 dissolution of individual module variants and dosage form variants, preliminary
investigations of drug release kinetics from cores only, MV1, and MV3, were performed in duplicate in
250 mL glass beakers containing 100 mL pH 6.8 phosphate buffer (I = 0.1 M), which maintained sink
conditions (relative to crystalline MS solubility) for MS dissolution. The purpose of this preliminary
release test was to guide selection of MV3 orifice size based on the orifice size that would provide
distinct drug release kinetics compared to MV1 and which could therefore be used to demonstrate
reconfigurability. Samples were suspended in the medium using a stainless steel stationary basket
analogous to that described in the USP 2 dissolution setup. This smaller scale dissolution test was
operated at room temperature with 500 rpm stirring with an Arex magnetic stirrer (VELP® Scientifica,
Usmate, Italy). At predefined time intervals, 1 mL aliquots were withdrawn. UV absorbance
spectrophotometry was used to quantify MS absorbance at 275 nm and MS concentration was
calculated from a calibration curve (concentration range 2–100 µg/mL). As an indication of homogeneity,
MS content was also determined along the length of the melt extruded filament by dissolving 5 mm
long filament sections (n = 10) weighing approximately 5 mg in 10 mL phosphate buffer and quantifying
MS via UV absorbance as described above.
MS concentrations in the aliquots withdrawn from the USP 2 dissolution apparatus were quantified
using a Waters Acquity UPLC system (Waters, Milford, MA, USA) featuring a binary solvent manager,
column manager, and sample manager. The UPLC system was equipped with a reversed phase
Acquity UPLC BEH C18 column (1.7 µm particle size, 2.1 mm inner diameter × 50 mm length) and an
Acquity UPLC PDA detector operated at 275 nm (Waters, MA, USA). MS calibration standards were
prepared ranging in concentration from 0.25 to 20 µg/mL for construction of a calibration curve and
subsequent quantification of MS concentrations in samples. The % relative standard deviation (RSD)
for all standard curves were below 5%. Of the standard or sample 10 uL was injected into a mobile
phase pumped at 1 mL/min through the column, maintained at 40 ◦C, in an isocratic gradient of 75%
water containing 0.03% trifluoroacetic acid and 25% acetonitrile containing 0.03% trifluoroacetic acid.
Empower 3 Chromatography Data Software (Waters, Milford, MA, USA) was used for both instrument
control and data analysis.
3. Results
3.1. Realization of the Product Concept
Functional realization of the product concept requires accurate and precise translation of the dose-
and drug release-determining design features into the physical construct. Table 1 shows the measured
mass and dimensions of the submodular components and/or specific features of interest for dose and
drug release in MV1 (no lid), MV2 (water soluble lid), and MV3 (water insoluble lid with orifice).
Pharmaceutics 2020, 12, 771 9 of 24
Table 1. Mass and measured dimensions of submodular components governing dose and drug release.
Submodular Component Mean Mass (mg) ± SD % RSD n Dose or ReleaseRate Determining
PLA cups 29.72 ± 0.32 1.1 50 dose and release
Core (normal fill) 28.82 ± 1.04 3.6 20 dose
Core (overfill) 33.97 ± 1.42 4.2 10 dose
Key Feature Length (mm) ± SD % RSD n Dose or ReleaseRate Determining
Core diameter 3.81 ± 0.11 2.8 48 release
MV2 lid thickness 0.57 ± 0.04 6.4 16 release
MV3 orifice diameter
(for 0.4 mm orifice) 0.39 ± 0.01 2.2 15 release
MS content measured along the length of the melt extruded filament was 39.4% ± 1.3% w/w.
With a % RSD of 3.2% in filament sections weighing approximately 5 mg, the filament was deemed
homogeneous on an approximately 6-fold smaller length scale than that required for core fabrication.
With this homogeneous distribution of MS in melt extruded filaments, the dose for MV1, MV2, and MV3
depended on reproducibility of both FDM-printed PLA cups and melt molded cores. FDM dispensing
precision of the PLA for the cups was high with a 1.1% RSD in mass. In contrast, the somewhat lower
precision in melt molded core mass of 3.6% and 4.2% RSD for normal filled cores (MV1 and MV2) and
overfilled cores (MV3), respectively, reflects the reliance on manual sectioning and filling of extruded
filaments into the PLA cup prior to melt molding, compared to the automated dispensing during FDM
to generate the PLA cups. Regardless, core masses were within an acceptable 5% RSD in all cases,
which, together with the filament drug content homogeneity, was expected to translate to acceptable
precision in dose.
The drug release rate-determining functionality was designed as the presence and/or type of lid
in each module variant given that the fastest drug release was provided by the core. This translated to
core diameter precision (2.8% RSD), lid thickness precision (6.4% RSD), and orifice diameter precision
(2.2% RSD) for MV1, MV2, and MV3. The dimensional data in Table 1 was obtained from X-ray
µCT images. The pixel size was adequate for the individual feature measurements. Contributions to
lid thickness variability, above the acceptable 5% RSD, is discussed in the X-ray µCT section below
(Section 3.3). Additionally, core diameter precision was also critical for MV2 since the drug release rate
after the water-soluble lid dissolves is dependent on the core diameter, analogous to MV1. For MV3,
the orifice diameter precision was measured for a target orifice diameter of 0.4 mm, which had an
acceptable 2.2% RSD in diameter. However, the final target orifice diameter for the MV3 constructs used
in subsequent drug release testing was 0.8 mm. Previous studies have shown that FDM dispensing
precision decreases with dispensing volume [70]. It can therefore be concluded that larger feature sizes
are expected to be generated with higher precision during FDM. Therefore, the final 0.8 mm orifice
precision is taken to be at least equivalent but expectedly higher than that of the 0.4 mm orifice.
3.2. Thermal Characterization
The cores are the dose-controlling features of all module variants and were melt molded from
melt extruded drug-containing filaments. Figure 4 shows the thermal transitions, which occurred
between 25 ◦C and 170 ◦C, of the raw materials for melt extrusion and the melt extruded filament
(40% w/w MS: 20% w/w PEG1500: 40% w/w VA64).
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Figure 4. Differential scanning calorimetry (DSC) traces of melt-extruded drug-containing filament
(red line) relative to raw materials included in the filament composition (black lines) whilst heating
from 25 to 170 ◦C.
Pure crystalline MS displayed a melting endotherm at 139 ◦C (Tm, midpoint). In the melt extruded
filament comprisi g 40% w/w MS: 20% w/w PEG1500, and 40% w/w VA64, melting endotherms were
visible in the region of PEG1500 and MS. The melting endotherm correspo ing to MS was bserved
in the melt extruded filament at a Tm of 130 ◦C. Comparing the melting enthalpies of pure cryst llin
MS with that of MS in the filament revealed a reduction in the melting en halpy from 178.7 to 68.1 J/g
(total weight). The melting enthalpy of pure crystalli e MS is in ag ement with that reported in the
literature [71]. Reduced melting enthalpies in the filament ar in part attributable to concentration
reduction from 100% in the raw materials to 40 MS and 20% PEG1500 in the fil ment. However,
this melting point depression was accompanied by a slight reduction i the degree of crystallinity
from 100% t 95.3% in the fila ent, indicating co version of some MS o the amo phous for and/or
solubilization of MS in the carrier/s [72]. A similar phenomenon wa observed in the region of PEG1500
in the filamen r sulting in a reduction in degre of crystallinity of PEG1500. I deed, r ported
Hansen solubility parameters of MS, PEG1500, d VA64 are similar at 21.7 MPa1/2 [73], 21.4 MPa1/2 [74],
and 21.5 MPa1/2 [75], respectively, supporting solubilization. The Tg of MS and PEG1500 below he
temperature rang of interest in this study was reported as 2.2 ◦C [73] for MS and −42 ◦C [76] for
PEG1500 in the existing literature. The Tg of VA64 was determ ed as approximately 111 ◦C determined
from heat cycle 2. Previous literature corroborates the pr sence of a characteristic broad endothermic
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peak between 25 and 100 ◦C due to water loss in heat cycle 1 and therefore Tg determination of
VA64 from heat cycle 2 [77]. All other DSC traces represent heat cycle 1. Despite the presence of
crystalline MS in the melt extruded filament, drug content was found to be homogeneous along the
length of the filament on a smaller length scale (approximately 5 mg filament) than that required for
core construction (approximately 29 mg filament). Since MS has a high aqueous solubility and the
module core was formulated as a rapidly eroding matrix, the relative contributions of amorphous
and crystalline MS was not expected to significantly alter the drug release performance of the module
variants. All processing, by FDM, HME, and melt molding, was performed below the degradation
temperatures of the raw materials, which were measured as 176 ◦C (MS), 311 ◦C (PEG1500), 276 ◦C
(VA64), 308 ◦C (PLA), and 270 ◦C (PVA).
3.3. X-Ray Computed Microtomography
Figure 5 shows longitudinal sections through the center of MV1, MV2, and MV3 (with 0.4 mm
orifice) and a cross section through MV2, revealing additional potential influences on drug release rates.
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Figure 5. Computed microtomographs of longitudinal sections through the midline of: (a) MV1;
(b) MV2; (c) MV3 with 0.4 mm orifice.
Figure 5 confirms that the cores were molded in direct contact with the inner walls and floor of the
PLA cups. PLA cup integrity was also verified through the absence of any defects traversing the wall or
floor of the PLA cup that could allow entry of dissolution media. Together, these results confirmed that,
as designed, the core diameter is expected to be release rate determining for MV1 and for MV2 after lid
dissolution. Figure 5 also shows that porosity was present in all cores after melt molding. Porosity has
been observed previously in melt-extruded VA64 filaments [78]. However, unlike the applied force
exerted by the screws during mixing in melt extrusion, we postulate that the melt molding process,
which involved loose stacking of filament sections in the cup followed by melting without any applied
force, was likely to contribute more to eventual core porosity. Three-dimensional image reconstruction
revealed that these pores were not interconnected throughout the matrix. Figure 5b, which represents
MV2, shows some sporadic over-deposition of PVA from the FDM nozzle in fabricating the lid, which
could influence lag times once polymer swelling and dissolution proceeds. Figure 5b,c reveal that,
in module variants with lids, cores with a normal fill volume created a headspace between the core and
the lid. This headspace and core porosity are both sources of air within MV3, which could contribute
to orifice obstruction or variable release kinetics [79]. Note that in final drug release tests involving
MV3, this headspace was eliminated by overfilling of the PLA cup with the core. The gaps visible
between the PLA cup walls and the lids were on the order of 200 µm or less at a fixed point, which
did not translate to looseness of fit and allowed the lids to remain attached to the cup either until lid
dissolution was complete (MV2) or throughout the drug release test (MV3).
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3.4. In Vitro Drug Release
Drug release kinetics for modules with varying orifice size are shown in Figure 6 in order to
aid final selection of the appropriate orifice size for MV3, which should display distinct drug release
kinetics to MV1 and allow reconfigurability to be demonstrated in final drug release tests. Preliminary
drug release testing in 250 mL media confirmed rapid and complete drug release from the free core
with a T80 of 10 min (Figure 6).





Figure 6. % Drug released vs.  time  for module variants with varying orifice size  to determine  the 
final orifice size for selection of MV3. The core only and MV1 with a 3.8 mm diameter exposed core 
face are presented as references. Data is presented as the minimum and maximum of n = 2 samples. 
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matrix comprising a water‐soluble drug in a water‐soluble PEG1500 and VA64 matrix. According to 
the  product  design,  rapid  release  from  the  core was  intended  to  allow  the  release  rate‐limiting 
features to be surface area of the exposed core face, lid thickness, and orifice size for MV1, MV2, and 
MV3, respectively. As expected, Figure 6 shows that drug release from MV1 (3.8 mm diameter  in 
Figure 6), with a T80 of 43 min, was  indeed slower  than  that of  the  free core due  to  the reduced 
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Figure 6. % Drug released vs. time for module variants with varying orifice size to determine the final
orifice size for selection of MV3. The core only and MV1 with a 3.8 mm diameter exposed core face are
presented as references. Data is presented as the minimum and maximum of n = 2 samples.
A reduction in the drug-containing core dimensions with respect to time was observed with
complete drug release evident once the entire core had dissolved. This was expected from a core
matrix comprising a water-soluble drug in a water-soluble PEG1500 and VA64 matrix. According to
the product design, rapid release from the core was intended to allow the release rate-limiting features
to be surface area of the exposed core face, lid thickness, and orifice size for MV1, MV2, and MV3,
respectively. As expected, Figure 6 shows that drug release from MV1 (3.8 mm diameter in Figure 6),
with a T80 of 43 min, was indeed slower than that of the free core due to the reduced surface area
available for hydration and subsequent drug dissolution. Figure 6 also illustrates drug release kinetics
as a function of lid orifice size, which was used to govern MV3 selection. Drug release kinetics with
progressively smaller orifice size revealed slower (T80 of 110 min) and mechanistically distinct release
kinetics at an orifice size of 0.8 mm, whereby initial drug release increased with time, in contrast to the
initial zero-order release exhibited by MV1. Compared to the 0.8 mm orifice size, orifice sizes ranging
from 1–2 mm (T80 of 52-65 min) all had similar release kinetics to MV1 indicating that the contribution
of initial hydration differences to the full release mechanism was not significant at this range of orifice
sizes. Consequently, an orifice size of 0.8 mm was selected for MV3. MV2 was designed to be identical
in release rate to MV1 after an initial lag period provided by the dissolution time of the water-soluble
PVA lid. Although the thickness of the lid would influence the duration of the lag phase, a lag phase
of any duration would differentiate MV2 release kinetics from that of MV1 and MV3. Consequently,
no preliminary drug release tests were required for the selection of MV2.
Figure 7 shows drug release kinetics for the final selected individual module variants MV1, MV2,
and MV3 under the USP 2 dissolution test conditions described in the methods section.
Pharmaceutics 2020, 12, 771 13 of 24





Figure 6. % Drug released vs.  time  for module variants with varying orifice size  to determine  the 
final orifice size for selection of MV3. The core only and MV1 with a 3.8 mm diameter exposed core 
face are presented as references. Data is presented as the minimum and maximum of n = 2 samples. 
A reduction  in  the drug‐containing core dimensions with respect  to  time was observed with 
complete drug release evident once  the entire core had dissolved. This was expected  from a core 
matrix comprising a water‐soluble drug in a water‐soluble PEG1500 and VA64 matrix. According to 
the  product  design,  rapid  release  from  the  core was  intended  to  allow  the  release  rate‐limiting 
features to be surface area of the exposed core face, lid thickness, and orifice size for MV1, MV2, and 
MV3, respectively. As expected, Figure 6 shows that drug release from MV1 (3.8 mm diameter  in 
Figure 6), with a T80 of 43 min, was  indeed slower  than  that of  the  free core due  to  the reduced 
surface area available for hydration and subsequent drug dissolution. Figure 6 also illustrates drug 
release  kinetics  as  a  function  of  lid  orifice  size, which was used  to  govern MV3  selection. Drug 
release  kinetics  with  progressively  smaller  orifice  size  revealed  slower  (T80  of  110  min)  and 
mechanistically distinct  release kinetics at an orifice  size of 0.8 mm, whereby  initial drug  release 
increased with time, in contrast to the initial zero‐order release exhibited by MV1. Compared to the 
0.8 mm orifice  size, orifice  sizes  ranging  from 1–2 mm  (T80 of 52‐65 min) all had  similar  release 







Figure 7  shows drug  release kinetics  for  the  final  selected  individual module variants MV1, 
MV2, and MV3 under the USP 2 dissolution test conditions described in the methods section. 
 
Figure 7. % Drug released vs. time for MV1 (blue), MV2 (black), and MV3 (red). Data is presented as
the minimum and maximum of n = 2 samples.
Three unique release profiles were obtained for the three module variants, with sufficient
reproducibility such that they could be used as the basis for reconfiguration into the final dosage form
variants. MV1 and MV2 exhibited mean T80 of 33 min and 110 min, respectively. Considering the
70 min lag phase during which the water-soluble PVA lid eroded, MV2 release kinetics after the lag
phase were comparable to MV1, as designed, with mean T80 for MV2 achieved approximately 40 min
after commencement of drug release. The lag phase for MV2 was provided by the lid swelling and
dissolution prior to drug release. The initially slower drug release rate between 70 and 80 min, before
the release rate reaches that of MV1, could be attributed to incomplete dissolution of the PVA lid,
initially exposing only a fraction of the intended core surface area to the dissolution medium, followed
by complete lid dissolution. Slower initial drug release kinetics were expected in MV3 compared to
MV1 due to the restricted access of dissolution media to the core through a 0.8 mm orifice, resulting in
slower core hydration and subsequent drug release at early time points. Indeed, the drug release rate
at 50% release (r50), measured as the gradient of a linear fit between 10% and 60% drug release [80],
was 2.5 and 1.7 for MV1 and MV3, respectively, confirming the success of this design feature.
MV1 and MV3 exhibited faster release kinetics under USP 2 test conditions relative to their
performance in preliminary drug release testing, which could be attributed to an increase in temperature
from room temperature (preliminary tests) to 37 ◦C (USP 2) as well as a change in the agitation method
from a magnetic stirrer to paddle apparatus. This temperature difference also contributed to a reduced
solubility of dissolved gases and formation of air bubbles in the USP 2 dissolution media, which
was not evident during preliminary tests. Air bubbles, originating from the medium, immobilized
periodically on the surface of MV1 and MV2, could temporarily reduce surface area available for
dissolution, contributing to the observed variability in individual release rates under USP 2 testing
conditions. This argument is supported by the lack of variability in individual release rates from MV3
due to the air bubble removal protocol described in the methods section applied to all MV3-containing
dissolution tests.
Figure 8 shows the dose released (mg) from the dosage form variants comprising two identical
module variants namely MV1+MV1, MV2+MV2, and MV3+MV3, in Figure 8a–c, respectively.
The solid lines represent minimum and maximum drug release kinetics for the dosage form
variants (black) and module variants (grey). Three unique release profiles are shown for the dosage
form variants comprising two identical module variants, analogous to that of the single module variants.
The dose released (mg) corresponds to the complete drug release (100%) in all cases. Furthermore,
Figure 8 also confirms that, in the absence of interactions between individual modules, both dose and
drug release kinetics from the dosage forms are a predictable net effect of the dose and drug release
kinetics of their constituent modules in all cases.
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form variants  comprising  two  identical module variants,  analogous  to  that of  the  single module 
variants.  The  dose  released  (mg)  corresponds  to  the  complete  drug  release  (100%)  in  all  cases. 
Furthermore, Figure 8 also confirms that, in the absence of interactions between individual modules, 
Figure 8. Dose released (mg) from dosage forms comprising two identical module variants:
(a) MV1+MV1; (b) MV2+MV2; and (c) V3+MV3. As a reference, solid grey lines indicate dose
released from single module variants. Data is presented as the minimum and maximum of n = 2
samples. Mean T50 and T80 values for the dosage forms are displayed in the bottom right of each figure.
Sources of variability for dosage forms constructed from MV1 and MV2 are as described for
Figure 7. Additionally, lag time variability in MV2 can be related to sporadic print defects of the
PVA lid as illustrated in Figure 5. The variability in dosage form variants constructed from MV3,
which was not observed in the release from an individual MV3, could potentially have originated
from adjacent placement of the module variants in the stationary basket, translating to differing
hydrodynamics around each module variant. Due to the orifice of MV3 limiting the surface area
available for hydration and matrix dissolution resulting in drug release, MV3 could exhibit a greater
sensitivity to hydrodynamic fluctuations than MV1 or MV2.
Figure 9 shows the dose released (mg) from the dosage form variants comprising two different
module variants namely MV1+MV2, MV1+MV3, and MV2+MV3, in Figure 9a–c, respectively.
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kinetics  compared  to  the  remaining  five dosage  form variants where  release  from both modules 
commence simultaneously. In this study, sequential release  is provided by the duration of the  lag 




form  and  their  individual  drug  release  kinetics  can  potentially  be  tailored  to  predictably  yield 
multimodal release profiles, each with a controlled delivered dose, from the dosage form. 
  
i r . Dose r leased (mg) from dosage forms comprising two dissimilar module variants:
(a) MV1+MV2; (b) MV1+MV3; and (c) 2+MV3. As a reference, solid grey lines indicate dose
released fro single module variants. Data is presented as the mi imum and maximum of n = 2
samples. Mean T50 and T80 values for the dosage forms are displayed in the bottom right of each figure.
The dose released (mg) corresponds to the complete drug release (100%) in all cases. As with
the combination of identical module variants in Figure 8, Figure 9 confirms that a combination of
dissimilar module variants to yield a dosage form also results in predictable, combined dose and drug
release kinetics from the dosage form as a net effect of that of their constituent module variants. Since
different module variants were combined, an additional three release profile variants were obtained on
the dosage form level. T50 and T80 values in Figure 8; Figure 9 together demonstrate that a total of six
release profile variants could be obtained from only three module variants, assuming the dosage form
comprises two module variants. Similar drug release profiles at the dosage form level (e.g., Figure 8a
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compared to Figure 9b) suggest that overall variety in dosage form release profiles could benefit from
a greater difference in individual module release profiles. Figure 9a demonstrates that drug release
from each module occurs sequentially resulting in bimodal release kinetics compared to the remaining
five dosage form variants where release from both modules commence simultaneously. In this study,
sequential release is provided by the duration of the lag phase in one of the modules. However,
sequential release can also be facilitated by alternative module designs and the order or pattern in
which they are assembled in a final dosage form. This indicates that, based on the desired in vitro
release profile on the dosage form level, for a particular drug product and/or therapeutic indication,
the number of module variants assembled into a dosage form and their individual drug release kinetics
can potentially be tailored to predictably yield multimodal release profiles, each with a controlled
delivered dose, from the dosage form.
4. Discussion
4.1. Key Study Outcomes and Concept Potential
This study demonstrated how enhanced product variety for multifunctional individualization can
be realized using reconfigurable modularization. Figure 10a,b depict key study outcomes. These include
the use of reconfigurable modularization to:
• Independently achieve predictable, combined dosing and predictable, combined drug release
kinetics for dosage forms based on their constituent modules and,
• Contribute to the enhanced product variety necessary for the provision of individualized therapy.


















































Figure 10. Summary of key demonstrated outcomes: (a,b); future potential of the concept to deliver
increased product variety predictably using reconfigurable modularization: (c).
These study outcomes were underpinned by key differences between our proposed modular
pharmaceutical product concept and conventional modular pharmaceutical product concepts, as
summarized in Table 2.
In both the conventional and proposed modular product concepts, assembly may be physical
assembly (e.g., gluing tablets, compression of bilayer tablets, and filling) [43,52,81], virtual assembly
(e.g., through CAD models or additive deposition of modules to generate a product during additive
manufacturing) [53,54,82,83], or hybrid assembly (e.g., compartmentalized devices, which can be
filled with s lids or liquids downstream) [44,84–86]. Importantly, rior to this demonstration of
reconfigurable modularization, for conventional modular pharmaceutical product concepts, beyond
customization, neither affordable customization nor the industrial adaption necessary for patient access
to individualized therapies were sufficiently addressed. In fact, even compartmentalized designs with
potential suitability for providing mutually independent dose, size, and release kinetics [44,53,54,61]
are not yet adapted to a unified product–process–production context for addressing the provision of
affordable variety and therefore patient access to individualized therapies. In response, in this study,
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product variety from a minimal number of modules is used as a simplified proxy for affordability.
Whilst a more in-depth analysis of affordability in the realization of mass customization capability is
highly desired, it is, albeit, beyond the scope of the present study. Accordingly, this study addressed a
key challenge and eventual goal in promoting affordability during individualization, that is, to generate
the maximum required number of finished product variants from a minimum number of module
variants. For the purpose of demonstrating the proposed concept, although a low degree of product
modularity was investigated (two modules in a dosage form), this principle was still evident through
the use of reconfiguration to generate six unique dosage form release profile variants from only three
module variants.
Table 2. Product modularization opportunities in the context of enhanced product variety during
mass customization.
Key Descriptor Conventional Modular Concepts Proposed Modular Concept
Purpose promotes process flexibility promotes process flexibility andproduct variety
Production context mass production—“economies ofscale”
mass customization—“economies of
scope”




typically achieved by iterative
modifications of single initial product
design
achieved by selection from multiple
initial product designs
Impact on product
variety-volume complexity variety OR affordability achievable variety AND affordability achievable
Impact on product design no. of module variants > no. ofproduct variants
no. of module variants < no. of
product variants
Beyond the demonstration of enhanced drug release flexibility independent of dose and the
increase in total variety of release profiles, this concept provides additional opportunities for expanding
flexibility while preserving affordability. Figure 10c illustrates that these include but are not limited to
(i) increasing the total range of release profile variants, (ii) increasing the total number of release profile
variants within a given range (fine-tuning a given release profile or obtaining new profiles), and (iii)
enhancing dose flexibility independent of drug release.
(i) Increase the total range of dosage form drug release profiles: the release rate and mechanism
is defined by the lid in our proposed product concept, either through the absence of the lid (MV1)
or through the lid material and design (MV2 and MV3). Alternative lid materials or designs could
therefore translate into alternative release kinetics or mechanisms for each module variant allowing
either slower or faster kinetics than those demonstrated in this study. Modification of only the lid
allows the balance between standardization and differentiation in the submodular components and the
total number of module variants to remain fixed. This balance is one already established approach to
simultaneously promote affordability (through standardization) and variety (through differentiation)
during mass customization [31,36]. In addition, the degree of product modularity (number of modules
assembled into a dosage form) demonstrated in this study was low, with a dosage form comprising
only two out of three available module variant designs. Still, with the proposed product concept,
reconfigurable assembly allowed an increased number of dosage form variants relative to module
variants. This demonstration of the role of reconfiguration in promoting affordable variety through
mass customization enables future exploration of the minimum number of product design modules
and module variants that can enable a maximum number of dosage form/product variants. Increasing
the number of module variants and/or the number of modules assembled into a dosage form (degree of
product modularity) could also promote increased variety. However, the economic feasibility of an
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increased number of modules and module variants, beyond our demonstration, will depend in part on
the volumes required of each relative to the overall gain in product variety.
(iia) Increase the total number of dosage form release profiles within a given range
(through fine-tuning): Current academic research on individualized release predominantly utilizes
a fine-tuning approach as a means to improve drug release flexibility, whereby modification of one
release-determining structural feature allows tuning of drug release iteratively, on a continuous
scale, and which confines variety in release profiles to variants of the same release profile shape or
mechanism. Examples include modifying shell thickness in core–shell designs to prolong or shorten
lag times [85,87], modifying porosity or the exposed surface area to obtain faster or slower kinetics
with the same release profile shape [88–90], and so forth. This is also attainable with our product
concept, for example, by modifying the exposed surface area of MV1 (as shown in Figure 6), modifying
lid thickness of MV2 to achieve different lag times, or reducing orifice size of MV3 to achieve slower
initial drug release kinetics. To support the latter, Table 1 indicates that 0.4 mm orifices can be printed
with high precision. Subsequent translation to robust performance needs to be ensured. Beyond the
smallest orifice size that can be printed with high precision, alternative approaches such as porous
materials achieved though mixtures of water-insoluble polymers with water-soluble pore formers
already exist [60,83,90–92]. This can not only provide fine-tuning as necessary for individualization
but also expands the range of accessible release profiles as described above. One caveat, despite the
technical potential for fine-tuning, is that the product variety–volume complexity challenge must be
considered to assess economic feasibility while increasing the number of module variants.
(iib) Increase the total number of dosage form drug release profiles within a given range
(through reconfiguration): Reconfiguration has been highlighted as a critical design feature of the
proposed modular product concept to increase the number of dosage form variants without increasing
the number of module variants that are designed and fabricated. Additionally, the dosage form
was constrained in size to enhance patient acceptability. Our modular design was based upon a
fixed target dosage form size of approximately 200 mm3 (corresponding to a standard 8 mm × 4 mm
flat-faced cylindrical tablet) to remain within the currently recommended dimensions of marketed
pharmaceutical tablets [93]. Since the modular product comprised only two modules, these were also
designed to be below approximately 100 mm3 each. Multifunctionality requires that the tailoring of
product features such as the dose and drug release be performed independently of each other and of
dosage form size [3]. Furthermore, we have assumed that a dosage form comprises any two out of
three available module variants. A dosage form consisting of a greater number of modules (whilst the
total number of module variants remain the same) is one approach to obtain greater flexibility through
reconfiguration. Since modular product concepts rely on the components of a dosage form being
smaller than the dosage form itself due to assembly, the more modules make up a dosage form,
the smaller the modules are required to be. Decreasing the size of modules could eventually be met
with a trade-off in robustness since an increase in the specific surface area at a smaller size is often
accompanied by an enhanced sensitivity to perturbations. A supporting example is the observed
variability in individual release kinetics of MV1 and MV2 in this study, which was attributed to
sensitivity to air bubbles in the test medium. Decreasing the module size is thus accompanied by strict
requirements on precision fabrication and robust performance.
(i) and (ii) Modify both the range and number of dosage form release profiles through combined
approaches: The total range of release kinetics selected in this study across the three module variants
allowed demonstration of predictable, combined “monophasic” drug release and predictable, combined
“biphasic” drug release. Since our results confirm that it is possible to construct dosage form release
profiles predictably from their constituent module release profiles, tailoring the time gap between
the release kinetics of one module variant and the next so that they are either more similar or less
similar to each other can either achieve an overlap or reduce the overlap between the combined release
profiles on a dosage form level. Tailoring the gap between module variant release kinetics together
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with modifying the number of modules that are reconfigured into a final dosage form can therefore
result in multiphasic release profiles, if desired, for certain APIs and/or therapeutic indications.
(iii) Simultaneously tailor dose and drug release: Although this study demonstrated additive
dosing from individual modules to final dosage forms, the delivered dose from the dosage form
remained fixed (although not identical) between dosage form variants. Identical doses within individual
module variants, if desired, could have been achieved through overfilling of MV1 and MV2 cores to
match overfilling of MV3 cores. Alternatively, achieving scalable individualized dosing with modular
dosage form design concepts at a fixed dosage form size was already addressed in our previous
work [70]. As described above, maintaining acceptable dosage form sizes independent of the dose
strength requires modules that are a fraction of the size of a conventional dosage form. However, it has
been exemplified, through a modular product design concept for improving dose flexibility, that a large
number of module variants are not necessary to yield high product variety, with only five module dose
variants capable of providing 100 product dose variants [68]. Consequently, the proposed modular
product concept can achieve simultaneous and independent tailoring of dose and drug release through
spatial separation of the entire dose from the release-controlling functionalities allowing predictable
modular dosing through modularization of the core [70] and predictable modular drug release.
4.2. Realization Challenges
Regarding individualized drug release, medical and biological knowledge gaps in defining
target individual in vivo release profiles remain. Optimization of the product and its subsequent
translation to in vivo performance was beyond the scope of this study. Nevertheless, our in vitro
demonstration of an increased variety of predictable drug release kinetics provides a pre-emptive step
towards realizing the overarching goals of individualized therapy, once these knowledge gaps are
filled. Furthermore, although independent tailoring of dose and drug release through modularization
was highlighted in this study, future explorations of modular product concepts for individualization
will need to be extended to encompass additional product attributes such as the appearance, choice of
API, composition, and sensory properties of a dosage form.
Robust functional realization and industrialization of our product concept and future product
concepts with their individualized attributes will rely, in part, on processing technologies’ capabilities
to fabricate parts reproducibly. Appropriate precision in FDM, HME, and melt molding was achieved
in this study for adequate prototyping of the product concept. However, to expand potential utility
of the concept and improve robustness of the module variants, alternative or modified formulations
and processing strategies (e.g., injection molding) can be exploited. These can, for example, reduce
core porosity and the contribution of air to orifice obstruction and variable release kinetics, achieve
complete amorphization in the filament for drugs with poor aqueous solubility, or facilitate automation
for increased throughput during scale-up and industrialization of the concept. The ability of the
selected processes to achieve high precision in dose-controlling, release-controlling, and size-controlling
structural features will remain critical.
Beyond product performance, unified integration with process and production will be required to
promote access to affordable individualized therapy. Whilst initial explorations of product designs
for individualization in a mass customization context have been performed [3,94], to this end,
further aspects of the unified approach, beyond product modularization, remain to be explored
(e.g., postponement and process flexibility) as enablers of a pharmaceutical mass customization
paradigm. Even adaption of modular pharmaceutical product concepts into a pharmaceutical mass
customization context still requires additional study areas, for example, establishment of appropriate
affordability metrics, subsequent assessments of affordability, and the role of the position and type of
module and product assembly steps in the pharmaceutical value chain, prior to their realization.
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5. Conclusions
Through the provision of an increased variety of drug release profiles independent of the dose and
size of the dosage form, a product concept for multifunctional individualization has been demonstrated.
To the best of our knowledge this is the first demonstration that fulfills a crucial overarching requirement
of pharmaceutical products for individualization, i.e., simultaneous and independent individualization
of multiple product features in the context of a unified product–process–production approach for the
provision of affordable variety.
The attainment of predictable, combined dosing and drug release with respect to the module
variants from which a dosage form is constructed highlights the role of reconfigurable modularization
in achieving predetermined dose and drug release accurately and predictably. In this regard, this study
provides a first indication of the potential to reverse engineer drug release kinetics for a dosage form,
from its composite module variants, based on a predetermined target release profile.
Furthermore, through reconfiguration during the final assembly stage (module variant to drug
product variant) to manage product variety, this product concept is primed to translate already
established key mass customization principles (process flexibility, modularization, and postponement)
to the pharmaceutical value chain. Although the road to realization still requires optimization for
robust performance, extended applicability to different APIs, and translation into clinical applicability,
the dynamic product design presented here provides numerous additional opportunities for expanding
flexibility, which remain to be harnessed prior to realization of affordable individualized therapy.
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